We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+10.11%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$47.1B
AUM Growth
+$2.61B
(+5.9%)
Cap. Flow
-$501M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
14.43%
Holding
3,576
New
705
Increased
706
Reduced
825
Closed
988
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walmart Inc
WMT
|
+$417M |
| 2 |
Meta Platforms (Facebook)
META
|
+$383M |
| 3 |
Amazon
AMZN
|
+$308M |
| 4 |
Microsoft
MSFT
|
+$293M |
| 5 |
GE Aerospace
GE
|
+$263M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$312M |
| 2 |
Bank of America
BAC
|
+$292M |
| 3 |
ExxonMobil
XOM
|
+$274M |
| 4 |
lululemon athletica
LULU
|
+$238M |
| 5 |
Qualcomm
QCOM
|
+$228M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.05% |
| 2 | Technology | 14.35% |
| 3 | Consumer Discretionary | 13.97% |
| 4 | Financials | 9.9% |
| 5 | Industrials | 6.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HBI
376
DELISTED
Hanesbrands
HBI
| $25.2M | 0.05% |
4,788,316
+4,537,925
| +1,812% | +$28.5M |
|
|
FITB
377
Fifth Third Bancorp
FITB
$52B
| $25.1M | 0.05% |
943,775
+435,388
| +86% | +$14.5M |
|
378
HealthEquity
HQY
$7.91B
| $25.1M | 0.05% |
427,786
-115,111
| -21% | -$6.99M |
|
379
Norwegian Cruise Line
NCLH
$8.89B
| $25.1M | 0.05% |
1,864,706
-2,365,346
| -56% | -$35.4M |
|
|
CTIC
380
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $25M | 0.05% |
+5,960,103
| New | +$30.9M |
|
|
JNPR
381
DELISTED
Juniper Networks
JNPR
| $24.9M | 0.05% |
724,770
+129,556
| +22% | +$4.1M |
|
382
ON Semiconductor
ON
$33.8B
| $24.9M | 0.05% |
302,154
+284,206
| +1,583% | +$21.6M |
|
383
Sarepta Therapeutics
SRPT
$1.66B
| $24.7M | 0.05% |
179,259
-6,746
| -4% | -$875K |
|
384
PagSeguro Digital
PAGS
$2.57B
| $24.7M | 0.05% |
2,878,006
+1,906,425
| +196% | +$17M |
|
385
Ashland
ASH
$3.04B
| $24.6M | 0.05% |
239,771
+117,349
| +96% | +$12.2M |
|
386
Healthcare Services Group
HCSG
$1.56B
| $24.6M | 0.05% |
1,774,393
+1,228,766
| +225% | +$16.2M |
|
387
Maravai LifeSciences
MRVI
$997M
| $24.6M | 0.05% |
1,752,939
-987,757
| -36% | -$14.2M |
|
388
Caesars Entertainment
CZR
$6.1B
| $24.5M | 0.05% |
501,339
+95,748
| +24% | +$4.69M |
|
389
Tenaris
TS
$29.1B
| $24.5M | 0.05% |
861,005
-22,428
| -3% | -$739K |
|
390
SM Energy
SM
$7.96B
| $24.5M | 0.05% |
868,832
-1,017,193
| -54% | -$31M |
|
|
NARI
391
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $24.4M | 0.05% |
+395,433
| New | +$23.7M |
|
|
JKS
392
JinkoSolar
JKS
$775M
| $24.4M | 0.05% |
477,992
+327,688
| +218% | +$17.2M |
|
393
RB Global
RBA
$20.8B
| $24.2M | 0.05% |
430,539
+403,222
| +1,476% | +$23.8M |
|
394
Royalty Pharma
RPRX
$26.1B
| $24.2M | 0.05% |
+672,530
| New | +$24.9M |
|
|
GHIX
395
DELISTED
Gores Holdings IX, Inc. Class A Common Stock
GHIX
| $24.1M | 0.05% |
2,387,493
| – | – |
|
396
Sally Beauty Holdings
SBH
$1.4B
| $24.1M | 0.05% |
1,543,749
+639,579
| +71% | +$9.94M |
|
397
Levi Strauss
LEVI
$9.44B
| $24M | 0.05% |
1,314,815
-259,445
| -16% | -$4.46M |
|
398
HEICO Corp Class A
HEI.A
$35.4B
| $23.9M | 0.05% |
176,056
-51,590
| -23% | -$6.84M |
|
399
Santander
BSBR
$39.7B
| $23.9M | 0.05% |
4,505,462
+3,763,275
| +507% | +$20.4M |
|
|
SCRM
400
DELISTED
Screaming Eagle Acquisition Corp. Class A Ordinary Shares
SCRM
| $23.7M | 0.05% |
2,333,385
| – | – |
|
Similar funds
Marshall Wace's Q1 2023 Portfolio in Review
As of Q1 2023, Marshall Wace held 3,576 positions worth $47.1B, up 5.9% from $44.5B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Marshall Wace's Q1 2023 filing shows 705 new, 706 increased, 825 reduced and 988 closed positions. Its largest new stake was Madrigal Pharmaceuticals: 541,764 shares worth $131M. The largest sale was Cigna, an estimated $312M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.
- Marshall Wace's largest Q1 2023 buy was Madrigal Pharmaceuticals: 541,764 shares worth $131M.
- Marshall Wace added most to Walmart Inc in Q1 2023, an estimated $417M increase.
- Marshall Wace's biggest Q1 2023 reduction was Cigna, cutting an estimated $312M.
- Marshall Wace fully exited Merck in Q1 2023, selling an estimated $115M.
- Marshall Wace's ten largest holdings make up 14% of its $47.1B portfolio in Q1 2023.
- Marshall Wace opened 705 new positions and closed 988 in Q1 2023.
- Marshall Wace's portfolio value rose 5.9% quarter-over-quarter to $47.1B.
Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.